Despite trial results showing that monoclonal antibody treatment can cause brain swelling and bleeding.
A much-anticipated new medication that aims to halt the cognitive decline in patients in the early stages of Alzheimer's disease was approved by the US Food and Drug Administration on Friday.
Leqembi, also known as lecanemab, received FDA approval just a few days after the FDA was harshly criticized by a congressional report for approving Aduhelm, another Alzheimer's drug.
In addition, it was approved despite the findings of a trial indicating that the monoclonal antibody treatment poses a risk of brain swelling and bleeding.
The FDA expedited the approval of both medications, allowing the US regulatory body to quickly approve medications for serious conditions for which there is an unmet medical need.
The FDA stated in a statement that Leqembi and Aduhelm, which were developed jointly by Japan's Eisai and the United States Biogen, "represent an important advancement in the ongoing fight to effectively treat Alzheimer's disease."
Billy Dunn of the FDA's Center for Drug Evaluation and Research stated in a statement, "Alzheimer's disease immeasurably incapacitates the lives of those who suffer from it and has devastating effects on their loved ones."
According to Dunn, Leqembi is "the latest therapy to target and affect the underlying disease process of Alzheimer's, rather than only treating the disease's symptoms."
In September, preliminary results from a Leqembi trial showed that it slowed Alzheimer's patients' cognitive decline by 27%.
Over the course of 18 months, nearly 1,800 participants in the phase three trial were randomly assigned to receive either the drug or a placebo.
The complete trial data, which were published in the New England Journal of Medicine, provided additional context for the findings and raised concerns regarding the frequency of "adverse effects," such as swelling and bleeds to the brain.
17.3% of patients who received the drug experienced brain bleeding, whereas 9% of those who received a placebo did not.
Additionally, whereas only 1.7% of those in the placebo group experienced brain swelling, 12.6% of those taking the drug did so.
In both arms of the drug trial, deaths were reported at about the same rate.
The accumulation of two essential proteins, tau and amyloid beta, into tangles and plaques—collectively referred to as aggregates—causes the death of brain cells and results in brain shrinkage in Alzheimer's disease.
Leqembi functions by focusing on amyloid.
Before Biogen and Eisai introduced Aduhelm to the market, there was a lot of debate about whether it worked, and its approval in 2021 led to three high-level FDA resignations.
An 18-month US congressional investigation found "rife with irregularities" in the Aduhelm approval process and criticized Biogen and the agency.
The congressional report stated that Biogen, based in Cambridge, Massachusetts, charged Aduhelm an "unjustifiably high price" of $56,000 per year.
According to Eisai, Leqembi would start out at $26,500 per year.
0 Comments